Published in J Am Coll Cardiol on January 01, 1995
Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know. J Thromb Thrombolysis (1995) 0.79
Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023). J Thromb Thrombolysis (1998) 0.77
Evolution of intracerebral hemorrhage after intravenous tPA: reversal of harmful effects with mast cell stabilization. J Cereb Blood Flow Metab (2013) 0.75
Consequence of patient substitution of nattokinase for warfarin after aortic valve replacement with a mechanical prosthesis. Proc (Bayl Univ Med Cent) (2015) 0.75
Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol (1997) 7.62
A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 6.82
Outbreak of hepatitis A among Italian patients with haemophilia. Lancet (1992) 5.64
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med (1999) 4.44
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 4.36
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med (2001) 4.33
The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem (1973) 4.24
Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg-->Gln mutation in the gene for factor V. N Engl J Med (1994) 4.00
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest (1987) 3.73
Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet (1985) 3.53
Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost (2006) 2.99
The separation of active and inactive forms of heparin. Biochem Biophys Res Commun (1976) 2.91
Eliminating parvovirus B19 from blood products. Lancet (1994) 2.85
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost (2005) 2.74
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 2.73
Effects of exposure to air pollution on blood coagulation. J Thromb Haemost (2006) 2.52
Benefits versus risks from mammography: a critical reassessment. Cancer (1996) 2.43
High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med (1998) 2.30
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol (1988) 2.28
Anticoagulant action of heparin. Nature (1973) 2.26
Isolation of a src homology 2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A (1992) 2.22
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost (2014) 2.15
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA (1999) 2.08
A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest (1998) 2.08
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
Actions and interactions of antithrombin and heparin. N Engl J Med (1975) 2.06
Current medicolegal and confidentiality issues in large, multicenter research programs. Am J Epidemiol (2000) 2.06
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet (1977) 2.06
Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost (2004) 2.04
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood (1996) 2.02
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost (2005) 2.02
Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem (1986) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res (1980) 2.00
Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem (1982) 1.99
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
Isolation and characterization of endothelial progenitor cells from mouse embryos. Development (1998) 1.94
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost (2004) 1.91
Mast cell clones: a model for the analysis of cellular maturation. J Cell Biol (1982) 1.91
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry (1985) 1.89
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost (2005) 1.83
Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed Proc (1977) 1.83
Correlation between structure and function of heparin. Proc Natl Acad Sci U S A (1979) 1.83
Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost (1996) 1.83
An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J Cell Biol (1985) 1.83
Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 1.81
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost (2011) 1.75
Molecular heterogeneity of inherited antithrombin III deficiency. N Engl J Med (1983) 1.75
Natural anticoagulant mechanisms. J Clin Invest (1984) 1.75
Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol (1997) 1.74
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J (2000) 1.73
Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry (1984) 1.70
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). J Thromb Haemost (2007) 1.67
Genetic screening for hemophilia A (classic hemophilia) with a polymorphic DNA probe. N Engl J Med (1985) 1.67
Structure-function relationships of heparin species. Proc Natl Acad Sci U S A (1978) 1.65
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost (2010) 1.62
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Effect on blood coagulation of massive intravascular haemolysis. Blood (1969) 1.61
Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet (1985) 1.60
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost (2005) 1.60
Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals novel substrate specificities. J Biol Chem (1999) 1.58
Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood (2000) 1.58
Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. Isolation, characterization, and expression of human cdnas and identification of distinct genomic loci. J Biol Chem (1999) 1.58
Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci U S A (1995) 1.58
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost (2012) 1.57
A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost (2001) 1.57
Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun (1985) 1.56
Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem (1976) 1.56
Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol (1993) 1.55
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost (2003) 1.53
The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease. J Thromb Haemost (2010) 1.52
Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III. Biochem Biophys Res Commun (2000) 1.51
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest (1984) 1.48
Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost (2006) 1.48
Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion (1995) 1.48
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood (1998) 1.47